Home › NDC Lookup › RxCUI directory › RxCUI 1099626

Divalproex sodium 125 MG Delayed Release Oral Tablet [Depakote] — RxCUI 1099626

RxNorm drug concept · Semantic branded drug
RxCUI 1099626 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1099626
Official nameDivalproex sodium 125 MG Delayed Release Oral Tablet [Depakote]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asDepakote 125 MG Delayed Release Oral Tablet
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)4,104 prescriptions · 26 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Divalproex: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats seizures, manic episodes of bipolar disorder, and prevents migraines. Which uses apply depends on the product. Capsules are only for seizures. Ask me to check which one y...
  • Swallow tablets whole and never crush or chew them. Extended-release tablets are once a day. Capsules can be swallowed whole or sprinkled on soft food and swallowed right away. Tak...
  • For delayed-release tablets, take it as soon as you remember unless it is almost time for the next dose. Do not double up. Ask your prescriber if you take another form.
  • Nausea, stomach upset, sleepiness, dizziness, tremor, headache and hair loss are common. Call your doctor if they bother you a lot. Call right away for severe stomach pain, vomitin...
📖 Read our full Divalproex guide →

🕸️ Concept Web — How Divalproex sodium 125 MG Delayed Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Divalproex sodium 125 MG Delayed Release Oral Tablet [Depakote] RxCUI 1099626

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Valproate 40254
    • Divalproex sodium 266856
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Depakote 216459
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Valproate Delayed Release Oral Tablet 808542
    • Divalproex sodium Delayed Release Oral Tablet 2646626
    • Valproate Oral Product 1159996
    • Valproate Pill 1159997
    • Divalproex sodium Oral Product 2663486
    • Divalproex sodium Pill 2659303
    • Valproate Delayed Release Oral Tablet [Depakote] 808545
    • Divalproex sodium Delayed Release Oral Tablet [Depakote] 2657391
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Divalproex sodium 125 MG Delayed Release Oral Tablet SCD · 1099625
  • Divalproex sodium 125 MG SCDC · 1099595
  • Valproate Delayed Release Oral Tablet SCDF · 808542
  • Divalproex sodium Delayed Release Oral Tablet SCDFP · 2646626
  • Valproate Oral Product SCDG · 1159996
  • Valproate Pill SCDG · 1159997
  • Divalproex sodium Oral Product SCDGP · 2663486
  • Divalproex sodium Pill SCDGP · 2659303

Brand-Name Concepts

  • Divalproex sodium 125 MG [Depakote] SBDC · 1099597
  • Valproate Delayed Release Oral Tablet [Depakote] SBDF · 808545
  • Divalproex sodium Delayed Release Oral Tablet [Depakote] SBDFP · 2657391
  • Depakote Oral Product SBDG · 1173098
  • Depakote Pill SBDG · 1173099
  • Depakote BN · 216459

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 1099626 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-7325-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (0074-7325-13) Depakote AbbVie Inc. 1983-03-10
00074-7326-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (0074-7326-13) Depakote AbbVie Inc. 2023-06-30
00074-7327-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (0074-7327-13) Depakote AbbVie Inc. 1983-03-10
Observed labelers: AbbVie Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.